Centessa Pharmaceuticals plc (NASDAQ:CNTA) released interim data from an ongoing Phase 1 trial of ORX750 in acutely sleep-deprived healthy volunteers.
ORX750 showed clinically meaningful and statistically significant improvements in mean sleep latency at the first two doses evaluated (1.0 mg and 2.5 mg) in the Maintenance of Wakefulness Test (MWT) compared to placebo.
MWT is a daytime sleep study that measures the ability to stay awake for a set period. It can help doctors evaluate how well the person responds to excessive sleepiness treatment.
The interim Phase 1 clinical data for ORX750 demonstrated:
ORX750 was also shown to have a favorable safety and tolerability profile with no observations of frequently reported on-target adverse events (AEs) associated with other OX2R agonists, and no cases of hepatotoxicity or visual disturbances across all three dose levels tested (1.0 mg, 2.0 mg, and 2.5 mg).
Based on the interim data, the company plans to advance ORX750 into Phase 2 studies in patients with narcolepsy type 1 and type 2, and idiopathic hypersomnia beginning in the fourth quarter of 2024.
Price Action: CNTA stock is up 7.90% at $16.11 at the last check on Tuesday.
Read Next:
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.